A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects

NCT01273103 | Withdrawn Phase 1

• 1 other identifier: 113393
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a Phase I, open-label, single dose, mass balance study in a cohort of 6 healthy adult male subjects. The study will consist of: Screening evaluations, a treatment phase, and follow-up evaluations. In the treatment phase, after an overnight fast of at least 10 hours, each subject will receive a single oral suspension dose of GSK2248761 200mg containing \[14C\] - GSK2248761. Following dosing, serial whole blood, plasma, urine, and fecal samples will be collected. Subjects will be required to remain in the unit until the radiocarbon excreted falls to less than or equal to 1% of the administered dose for two consecutive 24-hour collections in both urine and feces, whichever occurs first. Safety will be assessed by vital signs, 12-lead electrocardiogram (ECG), clinical laboratory tests, AE monitoring, and physical examinations as indicated.

Conditions

Infection, Human Immunodeficiency Virus

Outcome Measures

Primary Outcomes (19)

• Percent recovery of total radiocarbon in urine and feces

  up to 10 days

• Area under the concentration-time curve from time zero to last time of quantifiable concentration within a subject (AUC (0-t)) of total drug-related material (radiocarbon) in blood and plasma

  up to 10 days

• Area under the concentration-time curve from time zero extrapolated to infinite time (AUC (0-infinity)) of total drug-related material (radiocarbon) in blood and plasma

  up to 10 days

• Percentage of AUC(0-infinity) obtained by extrapolation (%AUCex) of total drug-related material (radiocarbon) in blood and plasma.

  up to 10 days

• Minimum observed concentration (Cmax) of total drug-related material (radiocarbon) in blood and plasma

  up to 10 days

• Time occurence of Cmax (tmax) of total drug-related material (radiocarbon) in blood and plasma

  up to 10 days

• Terminal phase rate constant (lambda z) of total drug-related material (radiocarbon) in blood and plasma

  up to 10 days

• Lag time before observation of drug concentrations in sampled matrix (tlag) of total drug-related material (radiocarbon) in blood and plasma

  up to 10 days

• Terminal phase half life (t1/2) of total drug-related material (radiocarbon) in blood and plasma

  up to 10 days

• AUC (0-t) of GSK2248761 in plasma

  up to 10 days

• AUC (0-infinity) of GSK2248761 in plasma

  up to 10 days

• %AUCex of GSK2248761 in plasma

  up to 10 days

• Cmax of GSK2248761 in plasma

  up to 10 days

• tmax of GSK2248761 in plasma

  up to 10 days

• Lambda z of GSK2248761 in plasma

  up to 10 days

• tlag of GSK2248761 in plasma

  up to 10 days

• Apparent clearance following oral dosing (CL/F) of GSK2248761 in plasma

  up to 10 days

• Apparent volume of distribution after oral administration (Vz/F) of GSK2248761 in plasma

  up to 10 days

• t1/2 of GSK2248761 in plasma

  up to 10 days

Secondary Outcomes (6)

• Safety and tolerability parameters including number of adverse events (AEs)

  up to 25 days

• Safety and tolerability parameters including change from baseline for vital signs (blood pressure and heart rate)

  up to 25 days

• Safety and tolerability parameters including change from baseline for electrocardiogram assessments (ECGs)

  up to 25 days

• Safety and tolerability parameters including change from baseline for clinical laboratory assessments

  up to 25 days

• Blood:plasma ratio of total drug-related material (radioactivity)

  up to 10 days

Study Arms (1)

Treatment

EXPERIMENTAL

\[14C\]- GSK2248761 200 mg

Drug: 200mg [14C]- GSK2248761

Interventions

200mg [14C]- GSK2248761 DRUG

single oral suspension dose of \[14C\]- GSK2248761 200 mg

Treatment

Eligibility Criteria

• Age: 30 Years - 55 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy as determined by a responsible physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
• Male subjects between 30 and 55 years of age.
• Male subjects must agree to use one of the contraception methods listed in the protocol. This criterion must be followed from the time of the first dose of study medication until 84 days after the dose of study medication. Male subjects also must refrain from the donation of sperm during this time as well.
• Body weight greater than or equal to 50 kg and body mass index (BMI) within the range 18.5-31.0 kg/m2 (inclusive).
• Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
• Available to complete the study (minimum of 7 and a maximum of 11 night's confinement in the clinical research unit).
• A history of regular bowel movements (averaging one or more bowel movements per day).
• AST, ALT, alkaline phosphatase and bilirubin greater than or equal to 1.5xULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%). A single repeat is allowed for eligibility determination.

You may not qualify if:

• The subject has a positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.
• The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
• History of sensitivity to any of the study medications, or components thereof, or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
• Use of prescription or non-prescription drugs, including antacids, vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
• If heparin is used during PK sampling, subjects with a history of sensitivity to heparin or heparin-induced thrombocytopenia should not be enrolled.
• History of regular alcohol consumption within 6 months of the study
• Has a history or regular use of tobacco- or nicotine-containing products within 3 months prior to screening.
• Consumption of red wine, seville oranges, grapefruit or grapefruit juice from 7 days prior to the first dose of study medication.
• Subjects who have received a total body radiation dose of greater than 5.0 mSv (upper limit of WHO category II) or exposure to significant radiation (e.g. serial x-ray or CT scans, barium meal etc) in the 12 months prior to this study. Any previous radiolabeled study drug must have been received more than 6 months prior to check-in. Also the total exposure from this current study and any previous studies must be within the recommended levels considered safe of 5 Rems whole body annual exposure, as per United States (US) Code of Federal Regulations (CFR) 21 CFR 361.1.
• Any condition that could interfere with the accurate assessment and recovery of radiocarbon \[14C\].
• Unwillingness or inability to follow the procedures outlined in the protocol.
• Subjects with a pre-existing condition interfering with normal gastrointestinal anatomy or motility, hepatic and/or renal function, that could interfere with the absorption, metabolism, and/or excretion of the study drugs. Subjects with a history of cholecystectomy should be excluded.
• A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
• A positive test for HIV antibody.
• Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.

Sponsors & Collaborators

• ViiV Healthcare: lead
• GlaxoSmithKline: collaborator

Study Sites (1)

GSK Investigational Site

Madison, Wisconsin, 53704, United States

Location

MeSH Terms

Conditions

Infections; Acquired Immunodeficiency Syndrome

Condition Hierarchy (Ancestors)

HIV Infections; Blood-Borne Infections; Communicable Diseases; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Slow Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases

Study Officials

• GSK Clinical Trials

  ViiV Healthcare

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 6, 2011
• First Posted: January 10, 2011
• Study Start: January 1, 2011
• Primary Completion: February 1, 2011
• Study Completion: February 1, 2011
• Last Updated: May 19, 2014

Record last verified: 2014-05

Locations

US (1)